(NASDAQ: VALN) Valneva Se's forecast annual revenue growth rate of 30.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.81%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Valneva Se's revenue in 2024 is $163,894,565.On average, 3 Wall Street analysts forecast VALN's revenue for 2024 to be $27,042,026,683, with the lowest VALN revenue forecast at $26,341,909,487, and the highest VALN revenue forecast at $27,558,779,851. On average, 3 Wall Street analysts forecast VALN's revenue for 2025 to be $35,502,609,604, with the lowest VALN revenue forecast at $33,944,571,019, and the highest VALN revenue forecast at $36,542,228,075.
In 2026, VALN is forecast to generate $51,507,233,132 in revenue, with the lowest revenue forecast at $40,009,475,139 and the highest revenue forecast at $58,275,032,690.